MEDIAIPLUS AI Clinical Trial Intelligence and CRO Matching

MEDIAIPLUS is a South Korean health-tech startup founded in 2019 and based in Seongnam, Gyeonggi-do, led by CEO Jihee Jung. It addresses the information gap in clinical development: data on trials and on which contract research organisations (CROs) are strong in which regions and therapy areas is scattered and hard for drug and device developers to compare.

Its platform draws on a database of about 29,700 CROs and more than 725,000 clinical trial records. A CRO matching service ranks providers by expertise, past performance, region and scope of work, and an AI curation tool gathers protocol design inputs such as drugs, diseases, modalities, guidelines, similar trials and competing products. The company has also launched MeA, a clinical trial chatbot. Users are pharmaceutical, biotech and medical device companies and the CROs that serve them.

• CRO matching: ranks CROs by expertise, past performance, region and scope of work.
• Global CRO database: about 29,700 CRO profiles worldwide.
• Trial records: more than 725,000 clinical trial records for benchmarking.
• AI protocol curation: collects drugs, diseases, modalities, guidelines and similar trials for design.
• Competitive intelligence: surfaces competing drugs and comparable studies.
• MeA chatbot: conversational assistant for clinical trial questions.

Vietnamese CROs can list on the platform to win studies from Korean and global sponsors. Domestic pharmaceutical companies planning bioequivalence or phase III trials can compare CROs and similar studies before tendering. Research hospitals can benchmark their trial portfolio against regional competitors.

Sponsors can shortlist CROs from a global database of about 29,700 providers instead of relying on personal networks. AI-curated protocol information speeds up trial design research. Local CROs gain a channel to reach foreign sponsors, which is the stated aim of the Vietnam partnership. The company claims its approach can shorten trial preparation and cut costs.

Korean, Japanese and Western biotech firms are placing more trials in Southeast Asia, and Vietnam has set a goal of becoming a regional clinical trial hub. Sponsors need faster ways to find qualified local CROs and sites. Vietnamese CROs, in turn, need visibility with foreign sponsors, which data-driven matching platforms can provide.

Founded in 2019; headquartered in Seongnam-si, Gyeonggi-do, South Korea; CEO Jihee Jung. Won an IFA 2025 Innovation Award and an SME AI Transformation Excellence Award (2025). Exhibited at MWC 2025. Signed an MOU on 11 July 2025 in Hanoi with Thang Long Institute of Medical and Pharmaceutical Research (IMP), a Vietnamese CRO.